ASTRAZENECA PLC

AZN

Explore Our Financial Data > Companies > ASTRAZENECA PLC

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AZN
CIK	0000901832
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, United Kingdom, CB2 0AA
Website	astrazeneca.com
Phone	011 44 20 7304 5000
CEO	Pascal Soriot
Employees	83,500

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$77.01 billion
Pre-Tax Income	$30.88 billion
Net Income	$30.88 billion
Net Income to Common	$30.90 billion
EPS	$6.54

View All

Balance Sheet

Cash	$5.71 billion
Assets	$114.07 billion
Liabilities	$65.36 billion
Common Equity	$11.96 billion
Liabilities & Equity	$112.63 billion

View All

Cash Flow Statement

Net Income	$30.88 billion
Cash From Operating Activities	$14.58 billion
Cash From Investing Activities	$-6.81 billion
Cash From Financing Activities	$-7.54 billion
Change in Cash	$223.00 million

View All

Calculations

NOPAT	$32.56 billion
EBITDA	$36.61 billion
Price to Earnings	$0.36
Price to Book	$0.93
ROE	71.20%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

WILMINGTON, Del., June 12, 2026--AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US Food and Drug Administration (FDA)-authorized test.1

Article Link

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State St

Article Link

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAPIn prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments1The FDA approval reinforces Roche’s leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomes Base

Article Link

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

European equities traded in the US as American depositary receipts were trending higher late Friday

Article Link

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

In the most recent trading session, Astrazeneca (AZN) closed at $182.28, indicating a +1.86% shift from the previous trading day.

Article Link